Hematology/Oncology @CleClinicMD | Associate Prof @CWRUSOM #mmsm
Cleveland, OH
Joined May 2018
- Tweets1.6K
- Following761
- Followers1.2K
- Likes6.5K
Jack Khouri retweeted
EPCORE DLBCL-2
Wow 😮
A lot of benefit—and a lot of $$$.
HR 0.49 is enormous: a 51% reduction in progression or death with epcoritamab + R-CHOP in frontline higher-risk DLBCL. This is not a marginal improvement and could redefine treatment.
But epcoritamab alone may add approximately $250,000 per patient at current US list price.
Now we need the curves: absolute PFS benefit, NNT, durability, OS, toxicity—and which biological subgroups benefit most. The signal is unquestionably impressive. The full dataset will tell us whether treating everyone is justified.
#DLBCL #HemeTwitter
Jack Khouri retweeted
Ok, looks like Epco-R-CHOP is ready for primetime.
HR 0.49 is impressive, and will probably be the new SoC.
What we eagerly wait:
1. Toxicity data
2. How Glofi-Pola-R-CHP will perform in the ph3 trial
3. Molecular data
Exciting times ahead!
Jack Khouri retweeted
With a plethora of options now for early relapsed (1-3 prior LoT) #Myeloma who are either naive or exposed/sensitive to anti-CD38-mAb (except CART-4 which had 25% CD38-refractory), how does the MRD-negative CR rates compare across regimens?
While BsAbs/CAR T remains at the top, impressive performance of Iber-Dara-Dex considering ~50% Len-refractory and 90% IMiD-exposed population. Remains to be seen how this translates into PFS!
#IMS26
Jack Khouri retweeted
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r
Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.
Jack Khouri retweeted
If you are in Glasgow #IMS26 stopby 12-1 pm poster- Mezigdomide post ide-cel in RRMM. We demonstrate in likited number that mezigdomide is safe as time limited maintenance for 1 yr at 0.6 mg.
imsannual2026.eventscribe.ne…
Jack Khouri retweeted
Now online @NatureComms, our manuscript describing why the myeloma CAR T cell cilta-cel is more effective than a very similar CAR, ide-cel.
Led by the very talented Kevin Herrera and Sneha Mitra, and in collaboration with the Leslie Laboratory.
@MSKCancerCenter @szusmani
Jack Khouri retweeted
The Other Renal Amyloids: It’s not ALL about AL Amyloid by @vsanchorawala
Amyloidosis isn’t synonymous with AL.
Renal differential ➡️ ATTR, AA, ALECT2, AFib, AApoAI, AApoAIV, AApoCII, ALys.
Typing the precursor protein determines treatment, prognosis and genetic implications.
Fully agree, Vaishali. Proud of this collaboration
These findings reinforce the important role of fat pad sampling as a first-line diagnostic test and highlight the complementary value of combining minimally invasive tissue approaches when evaluating suspected AL amyloidosis. @BU_Amyloidosis @ASH_hematology @BloodAdvances
Jack Khouri retweeted
Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis ashpublications.org/bloodadv…
Jack Khouri retweeted
Not all CHIP is created equal when it comes to CAR-T…TP53 mutant CHIP stands out:
➡️ more cytopenias, higher baseline CAR HEMATOTOX, reduced CAR expansion and inferior outcomes
➡️ distinct inflamm. proteomic signature
Just out in 📄 in @LeukemiaJnl
nature.com/articles/s41375-0…
Jack Khouri retweeted
Pancreatic cancer is notoriously hard to treat, but we are making progress. Recent @theNCI -funded work that sheds light on mechanisms behind #daraxonrasib resistance and could help clinicians choose treatment combos that outsmart pancreatic tumors. go.nih.gov/AcvCu95
Jack Khouri retweeted
Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-le… @BU_Amyloidosis
Jack Khouri retweeted
I am a strong supporter of human-relevant cancer models. New research, funded in part by @NIH, adds ~150 3D organoids across 10 cancer types to DepMap—preserving tumor biology that 2D lines miss and revealing drug targets that might never have been found. go.nih.gov/C2SNHoR
ALT Wild type human prostate cells from an organoid (a man-made construct that resembles an organ). These cells have come from a xenograft where they serve as controls for the study of primary prostate cancer tumor cells, which are also injected into mice and then extracted for characterization.
Jack Khouri retweeted
Another chapter of #downwithdex, this time for AL amyloidosis!
By the book, dex 20-40 mg QW for 6 months in ANDROMEDA. No need for this in real life.
No ∆ in efficacy; rise in CHF exacerbations and ⬆️ diuretics with prolonged dex.
I do 4-8 weeks of 12-20 mg then stop.
#Myeloma Paper of the Day: Limited duration (≤3 months) of dexamethasone in newly diagnosed AL #amyloidosis (w/ daratumumab-based regimen) results in higher 6-month CR rates (66.7 vs 30.4%, p<0.001) and reduced toxicity, similar organ responses: pubmed.ncbi.nlm.nih.gov/4256…. #alsm
Jack Khouri retweeted
A very fond farewell to #TimGilligan
as he begins his next chapter in San Francisco after 21 years at @CleClinicMD A wonderful colleague and friend, wishing him the best!
@khouri_jack @drrdean @n8pennell @aakonc @ChrisWeeMD @AmandaNizamMD @DemitriDedousis @jamecancerdoc @brian_rini @MosheOrnsteinMD @MoningiShalini @CleClinicUro @RTendulkarMD @DrOmarMian @cjweight @LauraBukavinaMD @KimAllman4 @PBarataMD @drjkaouk @PGrivasMDPhD @smitha42
Jack Khouri retweeted
#Myeloma Paper of the Day: 1F10, a novel high-affinity lambda subtype-specific amyloid-binding antibody enhances phagocytosis of amyloid; demonstrates robust activity in AL amyloidoma mouse model, accelerating resolution of lambda amyloid fibrils: pubmed.ncbi.nlm.nih.gov/4252…. #alsm
Jack Khouri retweeted
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial | Nature Medicine nature.com/articles/s41591-0…
So proud of our amazing @CCF_IMCHIEFS resident, soon to be @MayoHemeOnc fellow @utkarshgoel08 for publishing @CIBMTR analysis on time to best response and depth of response post idecel #CART #mmsm @BloodCancerJnl @VincentRK @ZanwarSaurabh @CleClinicMD nature.com/articles/s41408-0…
Jack Khouri retweeted
BCJ Impact Factor: 13.8.
Connect with Editors-in-Chief @VincentRK and Ayalew Tefferi regarding questions on submissions.
nature.com/bcj
Jack Khouri retweeted
Congrats @myelomaMD and @VincentRK on a very important academic trial to define optimal duration of therapy in standard risk TI MM. Caution not generalize these findings to limit duration of therapies (such as immune Rx) without proper randomized trials. nejm.org/doi/full/10.1056/NE…
